News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer
Praveen Kumar Marimuthu/X
May 1, 2025, 09:14

Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer

Praveen Kumar Marimuthu, DM Resident in Medical Oncology at Christian Medical College and Hospital, shared an article by Rebecca Kristeleit, et al. on X:

“Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer.

  • 12-wk PFS: 42%.
  • ORR: 25%.
  • Median DOR: 13.1 mo.
  • Median OS: 14.8 mo.”

Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer

Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical Trial.

Journal: Jama Network

Authors: Rebecca Kristeleit, Michael-John Devlin, Andrew Clamp, Charlie Gourley, René Roux, Marcia Hall, Rachel Nirsimloo, Valentinos Kounnis, Lesley Sage, Priya Narayanan, C. Simon Herrington, Rupali Arora, Laura Farrelly, Laura Hughes, Nicholas Counsel, Rowan E. Miller, et al.

You can Read the Full Article on Journal of JAMA NETWORK.

Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer

More posts featuring Praveen Kumar Marimuthu.

Advanced Clear Cell Gynecological Cancer Andrew Clamp C. Simon Herrington cancer Charlie Gourley Christian Medical College and Hospital clinical trial fight against cancer Global fight against cancer Gynecological Cancer JAMA Network Laura Farrelly Laura Hughes Lesley Sage Marcia Hall MedOnc Michael-John Devlin Nicholas Counsel OncoDaily Oncology pembrolizumab Praveen Kumar Marimuthu Priya Narayanan Rachel Nirsimloo Rebecca Kristeleit René Roux Rowan E. Miller Rupali Arora Valentinos Kounnis
Special Coverage
Blog
Jul 6, 2025, 08:26
"Behind Every Empowered Patient is a Dedicated Navigator" Webinar - Pink Africa Foundation
Insight
Jul 6, 2025, 07:47
Samuel Hume: 5 Medical Breakthroughs From June
Blog
Jul 6, 2025, 07:40
Wafik El-Deiry: WIN Consortium in Cancer Personalized Medicine Is Supporting the Tempus AI GEMINI-NSCLC Study
Blog
Jul 6, 2025, 07:09
Olubukola Ayodele: How to Shift from Acute to Community?
Blog
Jul 6, 2025, 02:27
A Public Hearing to Better Meet the Needs of Underserved Communities - European Cancer Organisation
Insight
Jul 5, 2025, 20:31
Diego A. Díaz García: Subclonal Immune Evasion in NSCLC
Blog
Jul 5, 2025, 20:15
Petros Grivas is Receiving 2025 Young Investigator Award
Blog
Jul 5, 2025, 20:00
Roberto Ferrara: Winter of Cancer Immunotherapy is Here
Blog
Jul 5, 2025, 19:42
Mario Balsa: TIME May Not Just Tell the Story - It Could Write the Prognosis STAR-01 at ESMOGI25
Blog
Jul 5, 2025, 19:18
Amol Akhade: CRC Screening Face-Off: Stool vs Blood
Blog
Jul 5, 2025, 18:53
Vivek Subbiah: How Clinical Trials Offer Hope for Those Facing Limited Options
Blog
Jul 5, 2025, 18:52
Saddened to Announce the Passing of Dr. Samantha Garza